Priority Assets


Our Priority Assets are largely maturing clinical development companies, nearing significant value inflection points.

Immunocore is a clinical-stage biotechnology company, based in Oxford, UK, building a new class of biologic drugs with novel T cell receptor (TCR) based technology for immunotherapies. Immunocore has developed proprietary technology focused on small protein molecules called Immune mobilising TCR Against Cancer (ImmTACs) which enable the immune system to recognise and kill cancerous or bacterially/virally infected cells.

Immunocore’s primary therapeutic focus is oncology, and it also has well-advanced programs in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development and its lead program, IMCgp100, is in ongoing pivotal clinical studies as a treatment for patients with metastatic uveal (eye) melanoma.

Within oncology, Immunocore is applying its ImmTAC platform to overcome the limitations of current anti-cancer therapies to deliver:

  • Potent and specific re-direction of a patient's own T cells to kill the target cancer cells.
  • Access to a pool of antigenic targets that is up to nine-fold greater than traditional antibody-based therapies.

This unique and potent mechanism of action provided by ImmTAC molecules gives the potential to tackle diverse tumour types, including solid tumours that are characteristically immune excluded, or "cold" and thus resistant to the majority of existing immunotherapies that target activation of pre-existing immune cells. ImmTAC molecules have the potential to convert "cold" tumours to "hot" through their T cell redirectly activity.

Immunocore's transformation science and strong IP position has led to multi-target discovery partnerships with Genentech, GlaxoSmithKline, MedImmune (AstraZeneca) and Eli Lilly to devlelop new cancer therapies using the ImmTAC technology platform.

Outside of oncology, the Bill and Melinda Gates Foundation is supporting the expansion of Immunocore's technology platform to develop ImmTAV and ImmTAB molecules for the treatment of infectious diseases.

Immunocore Pipeline

Candidate

Indication

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal

IMCgp100

Uveal melanoma

IMCgp100 checkpoint combination

Cutaneous melanoma

GSK1 (IMCnyeso)

Synovial / bladder / melanoma /
non-small cell lung cancer

IMC-C103C

Non-small cell lung cancer /
oesophageal / others

IMC-F106C

Non-small cell lung cancer /
breast / ovarian / others

IMC-G107C

Liver / breast / ovarian / endometrial / others

Candidate: IMCgp100

Indication: Uveal melanoma

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal


Candidate: IMCgp100 checkpoint combination

Indication: Cutaneous melanoma

Owner: Immunocore / MedImmune

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal


Candidate: GSK1 (IMCnyeso)

Indication: Synovial / bladder / melanoma /
non-small cell lung cancer

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal


Candidate: IMC-C103C

Indication: Non-small cell lung cancer /
oesophageal / others

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal


Candidate: IMC-F106C

Indication: Non-small cell lung cancer /
breast / ovarian / others

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal


Candidate: IMC-G107C

Indication: Liver / breast / ovarian / endometrial / others

ImmTAC generation

IND-enabling

Phase 1 / 2

Pivotal